BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

856 related articles for article (PubMed ID: 18022866)

  • 1. Crohn's disease activity assessed by fecal calprotectin and lactoferrin: correlation with Crohn's disease activity index and endoscopic findings.
    Sipponen T; Savilahti E; Kolho KL; Nuutinen H; Turunen U; Färkkilä M
    Inflamm Bowel Dis; 2008 Jan; 14(1):40-6. PubMed ID: 18022866
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Fecal calprotectin, lactoferrin, and endoscopic disease activity in monitoring anti-TNF-alpha therapy for Crohn's disease.
    Sipponen T; Savilahti E; Kärkkäinen P; Kolho KL; Nuutinen H; Turunen U; Färkkilä M
    Inflamm Bowel Dis; 2008 Oct; 14(10):1392-8. PubMed ID: 18484671
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Fecal calprotectin correlates more closely with the Simple Endoscopic Score for Crohn's disease (SES-CD) than CRP, blood leukocytes, and the CDAI.
    Schoepfer AM; Beglinger C; Straumann A; Trummler M; Vavricka SR; Bruegger LE; Seibold F
    Am J Gastroenterol; 2010 Jan; 105(1):162-9. PubMed ID: 19755969
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Relationships between disease activity and serum and fecal biomarkers in patients with Crohn's disease.
    Jones J; Loftus EV; Panaccione R; Chen LS; Peterson S; McConnell J; Baudhuin L; Hanson K; Feagan BG; Harmsen SW; Zinsmeister AR; Helou E; Sandborn WJ
    Clin Gastroenterol Hepatol; 2008 Nov; 6(11):1218-24. PubMed ID: 18799360
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Fecal calprotectin is a surrogate marker for endoscopic lesions in inflammatory bowel disease.
    D'Haens G; Ferrante M; Vermeire S; Baert F; Noman M; Moortgat L; Geens P; Iwens D; Aerden I; Van Assche G; Van Olmen G; Rutgeerts P
    Inflamm Bowel Dis; 2012 Dec; 18(12):2218-24. PubMed ID: 22344983
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Serum calprotectin as a biomarker for Crohn's disease.
    Meuwis MA; Vernier-Massouille G; Grimaud JC; Bouhnik Y; Laharie D; Piver E; Seidel L; Colombel JF; Louis E;
    J Crohns Colitis; 2013 Dec; 7(12):e678-83. PubMed ID: 23845231
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A prospective study of fecal calprotectin and lactoferrin as predictors of small bowel Crohn's disease in patients undergoing capsule endoscopy.
    Bar-Gil Shitrit A; Koslowsky B; Livovsky DM; Shitrit D; Paz K; Adar T; Adler SN; Goldin E
    Scand J Gastroenterol; 2017 Mar; 52(3):328-333. PubMed ID: 27841040
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Correlation of faecal calprotectin and lactoferrin with an endoscopic score for Crohn's disease and histological findings.
    Sipponen T; Kärkkäinen P; Savilahti E; Kolho KL; Nuutinen H; Turunen U; Färkkilä M
    Aliment Pharmacol Ther; 2008 Nov; 28(10):1221-9. PubMed ID: 18752630
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Assessment of the response of patients with Crohn's disease to biological therapy using new non-invasive markers: lactoferrin and calprotectin.
    Nogueira IM; Miszputen SJ; Ambrogini O; Artigiani-Neto R; Carvente CT; Zanon MI
    Arq Gastroenterol; 2013 Apr; 50(2):130-7. PubMed ID: 23903623
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Noninvasive markers in the assessment of intestinal inflammation in inflammatory bowel diseases: performance of fecal lactoferrin, calprotectin, and PMN-elastase, CRP, and clinical indices.
    Langhorst J; Elsenbruch S; Koelzer J; Rueffer A; Michalsen A; Dobos GJ
    Am J Gastroenterol; 2008 Jan; 103(1):162-9. PubMed ID: 17916108
    [TBL] [Abstract][Full Text] [Related]  

  • 11. A new rapid test for fecal calprotectin predicts endoscopic remission and postoperative recurrence in Crohn's disease.
    Lobatón T; López-García A; Rodríguez-Moranta F; Ruiz A; Rodríguez L; Guardiola J
    J Crohns Colitis; 2013 Dec; 7(12):e641-51. PubMed ID: 23810085
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Role of capsule endoscopy and fecal biomarkers in small-bowel Crohn's disease to assess remission and predict relapse.
    Aggarwal V; Day AS; Connor S; Leach ST; Brown G; Singh R; Friedman A; Zekry A; Craig PI
    Gastrointest Endosc; 2017 Dec; 86(6):1070-1078. PubMed ID: 28947363
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Fecal lactoferrin and calprotectin after ileocolonic resection for Crohn's disease.
    Scarpa M; D'Incà R; Basso D; Ruffolo C; Polese L; Bertin E; Luise A; Frego M; Plebani M; Sturniolo GC; D'Amico DF; Angriman I
    Dis Colon Rectum; 2007 Jun; 50(6):861-9. PubMed ID: 17473939
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Faecal calprotectin and magnetic resonance imaging in detecting Crohn's disease endoscopic postoperative recurrence.
    Baillet P; Cadiot G; Goutte M; Goutorbe F; Brixi H; Hoeffel C; Allimant C; Reymond M; Obritin-Guilhen H; Magnin B; Bommelaer G; Pereira B; Hordonneau C; Buisson A
    World J Gastroenterol; 2018 Feb; 24(5):641-650. PubMed ID: 29434453
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Measurement of fecal calprotectin improves monitoring and detection of recurrence of Crohn's disease after surgery.
    Wright EK; Kamm MA; De Cruz P; Hamilton AL; Ritchie KJ; Krejany EO; Leach S; Gorelik A; Liew D; Prideaux L; Lawrance IC; Andrews JM; Bampton PA; Jakobovits SL; Florin TH; Gibson PR; Debinski H; Macrae FA; Samuel D; Kronborg I; Radford-Smith G; Selby W; Johnston MJ; Woods R; Elliott PR; Bell SJ; Brown SJ; Connell WR; Day AS; Desmond PV; Gearry RB
    Gastroenterology; 2015 May; 148(5):938-947.e1. PubMed ID: 25620670
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Association of Biomarker Cutoffs and Endoscopic Outcomes in Crohn's Disease: A Post Hoc Analysis From the CALM Study.
    Reinisch W; Panaccione R; Bossuyt P; Baert F; Armuzzi A; Hébuterne X; Travis S; Danese S; Sandborn WJ; Schreiber S; Berg S; Zhou Q; Kligys K; Neimark E; Suleiman AA; D'Haens G; Colombel JF
    Inflamm Bowel Dis; 2020 Sep; 26(10):1562-1571. PubMed ID: 32105310
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The diagnostic usefulness of fecal lactoferrin in the assessment of Crohn's disease activity.
    Klimczak K; Lykowska-Szuber L; Eder P; Krela-Kazmierczak I; Stawczyk-Eder K; Szymczak A; Michalak M; Studniarek A; Linke K
    Eur J Intern Med; 2015 Oct; 26(8):623-7. PubMed ID: 26198785
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Impact of disease location on fecal calprotectin levels in Crohn's disease.
    Gecse KB; Brandse JF; van Wilpe S; Löwenberg M; Ponsioen C; van den Brink G; D'Haens G
    Scand J Gastroenterol; 2015 Jul; 50(7):841-7. PubMed ID: 25636819
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Accurate cut-offs for predicting endoscopic activity and mucosal healing in Crohn's disease with fecal calprotectin.
    Vázquez Morón JM; Pallarés Manrique H; Machancoses FH; Ramos Lora M; Ruiz Frutos C
    Rev Esp Enferm Dig; 2017 Feb; 109(2):130-136. PubMed ID: 28071062
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Comparison of Fecal Inflammatory Markers in Crohn's Disease.
    Wright EK; Kamm MA; De Cruz P; Hamilton AL; Ritchie KJ; Keenan JI; Leach S; Burgess L; Aitchison A; Gorelik A; Liew D; Day AS; Gearry RB
    Inflamm Bowel Dis; 2016 May; 22(5):1086-94. PubMed ID: 26818420
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 43.